Literature DB >> 27387455

Management of Inflammatory Bowel Disease in the Elderly.

Elizabeth S John1,2, Kristina Katz3, Mark Saxena3, Sita Chokhavatia3, Seymour Katz4.   

Abstract

OPINION STATEMENT: A substantial and growing proportion of patients with inflammatory bowel disease (IBD) are elderly, and these patients require tailored treatment strategies. However, significant challenges exist in the management of this population due to the paucity of data. Establishing the initial diagnosis and assessing the etiology of future symptoms and flares can be challenging as several other prevalent diseases can masquerade as IBD, such as ischemic colitis, diverticular disease, and infectious colitis. Important pharmacologic considerations include reduced glomerular filtration rate and drug-drug interactions in the elderly. No drug therapy is absolutely contraindicated in this population; however, special risk and benefit assessments should be made. Older patients are more susceptible to side effects of steroids such as delirium, fractures, and cataracts. Budesonide can be an appropriate alternative for mild to moderate ulcerative colitis (UC) or Crohn's disease (CD) as it has limited systemic absorption. Pill size and quantity, nephrotoxicity, and difficulty of administration of rectal preparations should be considered with 5-aminosalicylic (5-ASA) therapy. Biologics are very effective, but modestly increase the risk of infection in a susceptible group. Based on their mechanisms, integrin receptor antagonists (e.g., vedolizumab) may reduce these risks. Use of antibiotics for anorectal or fistulizing CD or pouchitis in UC increases the risk of Clostridium difficile infection. Pre-existing comorbidities, functional status, and nutrition are important indicators of surgical outcomes. Morbidity and mortality are increased among IBD patients undergoing surgery, often due to postoperative complications or sepsis. Elderly adults with IBD, particularly UC, have very high rates of venous thromboembolism (VTE). Colonoscopy appears safe, but the optimal surveillance interval has not been well defined. Should the octogenarian, nonagenarian, and centurion undergo colonoscopy? The length of surveillance should likely account for the individual's overall life expectancy. Specific health maintenance should emphasize administering non-live vaccines to patients on thiopurines or biologics and regular skin exams for those on thiopurines. Smoking cessation is crucial to overall health and response to medical therapy, even among UC patients. This article will review management of IBD in the elderly.

Entities:  

Keywords:  Crohn’s disease; Elderly; IBD; Management; Ulcerative colitis

Year:  2016        PMID: 27387455     DOI: 10.1007/s11938-016-0099-6

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  96 in total

1.  Survival in elderly patients with ulcerative colitis and colorectal cancer.

Authors:  Wojciech Blonski; Gary R Lichtenstein
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

2.  Predictors of early response to infliximab in patients with ulcerative colitis.

Authors:  Marc Ferrante; Séverine Vermeire; Konstantinos H Katsanos; Maja Noman; Gert Van Assche; Fabian Schnitzler; Ingrid Arijs; Gert De Hertogh; Ilse Hoffman; J Karel Geboes; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2007-02       Impact factor: 5.325

3.  Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study.

Authors:  Uri Kopylov; Maria Vutcovici; Abbas Kezouh; Ernest Seidman; Alain Bitton; Waqqas Afif
Journal:  Inflamm Bowel Dis       Date:  2015-08       Impact factor: 5.325

Review 4.  Systematic review with meta-analysis: inflammatory bowel disease in the elderly.

Authors:  J P Gisbert; M Chaparro
Journal:  Aliment Pharmacol Ther       Date:  2014-01-09       Impact factor: 8.171

5.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

6.  Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination.

Authors:  T Craig Cheetham; S Michael Marcy; Hung-Fu Tseng; Lina S Sy; In-Lu Amy Liu; Felicia Bixler; Roger Baxter; James G Donahue; Allison L Naleway; Steven J Jacobsen
Journal:  Mayo Clin Proc       Date:  2015-06-04       Impact factor: 7.616

7.  Factors affecting surgical risk in elderly patients with inflammatory bowel disease.

Authors:  Michael J Page; Lisa S Poritz; Susan J Kunselman; Walter A Koltun
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

Review 8.  Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

Authors:  Leon P McLean; Terez Shea-Donohue; Raymond K Cross
Journal:  Immunotherapy       Date:  2012-09       Impact factor: 4.196

9.  Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients.

Authors:  Geoffrey C Nguyen; Justina Sam
Journal:  Am J Gastroenterol       Date:  2008-08-05       Impact factor: 10.864

10.  Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers.

Authors:  Shilpa Joshi; Stephen J Lewis; Siobhan Creanor; Ruth M Ayling
Journal:  Ann Clin Biochem       Date:  2009-09-09       Impact factor: 2.057

View more
  7 in total

Review 1.  Inflammatory Bowel Disease in the Baby to Baby Boomer: Pediatric and Elderly Onset of IBD.

Authors:  Anita Afzali; Seymour Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2018-09

2.  Serious and Opportunistic Infections in Elderly Patients With Inflammatory Bowel Disease.

Authors:  Elissa Lin; Kevin Lin; Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-11

3.  Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study.

Authors:  Preeti Shashi; Dharmesh Gopalakrishnan; Malav P Parikh; Bo Shen; Gursimran Kochhar
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-09-17

Review 4.  Outcomes and Management of the Ileal Pouch-Anal Anastomosis in the Elderly.

Authors:  James Q Zhou; Sean Michael Duenas; Tarik Kirat; Feza Remzi; Shannon Chang
Journal:  Curr Treat Options Gastroenterol       Date:  2018-09

5.  Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.

Authors:  Nabeel Khan; Carlos Vallarino; Trevor Lissoos; Umar Darr; Michelle Luo
Journal:  Drugs Aging       Date:  2017-11       Impact factor: 3.923

6.  Decreased CD8+CD28+/CD8+CD28- T cell ratio can sensitively predict poor outcome for patients with complicated Crohn disease.

Authors:  Shi-Xue Dai; Hong-Xiang Gu; Qian-Yi Lin; Yan-Kun Wu; Xiao-Yan Wang; Shao-Zhuo Huang; Tiao-Si Xing; Min-Hua Chen; Qing-Fang Zhang; Zhong-Wen Zheng; Wei-Hong Sha
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

7.  Ischemic or toxic injury: A challenging diagnosis and treatment of drug-induced stenosis of the sigmoid colon.

Authors:  Zong-Ming Zhang; Xiang-Chun Lin; Li Ma; An-Qin Jin; Fang-Cai Lin; Zhuo Liu; Li-Min Liu; Chong Zhang; Na Zhang; Li-Juan Huo; Xue-Liang Jiang; Feng Kang; Hong-Jun Qin; Qiu-Yang Li; Hong-Wei Yu; Hai Deng; Ming-Wen Zhu; Zi-Xu Liu; Bai-Jiang Wan; Hai-Yan Yang; Jia-Hong Liao; Xu Luo; You-Wei Li; Wen-Ping Wei; Meng-Meng Song; Yue Zhao; Xue-Ying Shi; Zhao-Hui Lu
Journal:  World J Gastroenterol       Date:  2017-06-07       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.